Literature DB >> 29669818

Changes in Glomerular Filtration Rate and Impact on Long-Term Survival among Adults after Hematopoietic Cell Transplantation: A Prospective Cohort Study.

Sangeeta Hingorani1,2,3, Emily Pao3, Phil Stevenson2, Gary Schoch2, Benjamin L Laskin4, Ted Gooley2, George B McDonald5,2.   

Abstract

BACKGROUND AND OBJECTIVES: Kidney injury is a significant complication for patients undergoing hematopoietic cell transplantation (HCT), but few studies have prospectively examined changes in GFR in long-term survivors of HCT. We described the association between changes in GFR and all-cause mortality in patients up to 10 years after HCT. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a prospective, observational cohort study of adult patients undergoing HCT at the Fred Hutchinson Cancer Center in Seattle, Washington from 2003 to 2015. Patients were followed from baseline, before conditioning therapy, until a maximum of 10 years after transplant. We used Cox proportional hazard models to examine the association between creatinine eGFR and all-cause mortality. We used time-dependent generalized estimating equations to examine risk factors for decreases in eGFR.
RESULTS: A total of 434 patients (median age, 52 years; range, 18-76 years; 64% were men; 87% were white) were followed for a median 5.3 years after HCT. The largest decreases in eGFR occurred within the first year post-transplant, with the eGFR decreasing from a median of 98 ml/min per 1.73 m2 at baseline to 78 ml/min per 1.73 m2 by 1 year post-HCT. Two thirds of patients had an eGFR<90 ml/min per 1.73 m2 at 1 year after transplant. When modeled as a continuous variable, as eGFR declined from approximately 60 ml/min per 1.73 m2, the hazard of mortality progressively increased relative to a normal eGFR of 90 ml/min per 1.73 m2 (P<0.001). For example, when compared with an eGFR of 90 ml/min per 1.73 m2, the hazard ratios for eGFR of 60, 50, and 40 ml/min per 1.73 m2 are 1.15 (95% confidence interval, 0.87 to 1.53), 1.68 (95% confidence interval, 1.26 to 2.24), and 2.67 (95% confidence interval, 1.99 to 3.60), respectively. Diabetes, hypertension, acute graft versus host disease, and cytomegalovirus infection were independently associated with a decline in GFR, whereas calcineurin inhibitor levels, chronic graft versus host disease, and albuminuria were not.
CONCLUSIONS: Adult HCT recipients have a high risk of decreased eGFR by 1 year after HCT. Although eGFR remains fairly stable thereafter, a decreased eGFR is significantly associated with higher risk of mortality, with a progressively increased risk as eGFR declines.
Copyright © 2018 by the American Society of Nephrology.

Entities:  

Keywords:  Adult; Behavior Therapy; Calcineurin Inhibitors; Graft versus Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Proportional Hazards Models; Survivors; Washington; albuminuria; creatinine; diabetes mellitus; glomerular filtration rate; hypertension; kidney; kidney dysfunction; mortality; risk factors

Mesh:

Year:  2018        PMID: 29669818      PMCID: PMC5989688          DOI: 10.2215/CJN.10630917

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  23 in total

1.  Acute renal failure after myeloablative hematopoietic cell transplant: incidence and risk factors.

Authors:  Sangeeta R Hingorani; Katherine Guthrie; Ami Batchelder; Gary Schoch; Nada Aboulhosn; Janel Manchion; George B McDonald
Journal:  Kidney Int       Date:  2005-01       Impact factor: 10.612

2.  Urinary elafin and kidney injury in hematopoietic cell transplant recipients.

Authors:  Sangeeta Hingorani; Laura S Finn; Emily Pao; Rick Lawler; Gary Schoch; George B McDonald; Behzad Najafian; Brenda Sandmaier; Ted Gooley
Journal:  Clin J Am Soc Nephrol       Date:  2014-11-11       Impact factor: 8.237

3.  The significant impact of acute kidney injury on CKD in patients who survived over 10 years after myeloablative allogeneic SCT.

Authors:  T Shimoi; M Ando; W Munakata; T Kobayashi; K Kakihana; K Ohashi; H Akiyama; H Sakamaki
Journal:  Bone Marrow Transplant       Date:  2012-05-28       Impact factor: 5.483

4.  Estimating glomerular filtration rate from serum creatinine and cystatin C.

Authors:  Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey
Journal:  N Engl J Med       Date:  2012-07-05       Impact factor: 91.245

5.  GVHD-associated chronic kidney disease after allogeneic haematopoietic cell transplantation.

Authors:  I Sakellari; A Barbouti; G Bamichas; D Mallouri; P Kaloyannidis; S Fragidis; I Batsis; C Apostolou; A Karpouza; E Yannaki; C Smias; K Sombolos; A Anagnostopoulos
Journal:  Bone Marrow Transplant       Date:  2013-04-15       Impact factor: 5.483

6.  Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis.

Authors:  Siribha Changsirikulchai; David Myerson; Katherine A Guthrie; George B McDonald; Charles E Alpers; Sangeeta R Hingorani
Journal:  Clin J Am Soc Nephrol       Date:  2009-01-14       Impact factor: 8.237

Review 7.  Chronic kidney disease after hematopoietic cell transplantation: a systematic review.

Authors:  M J Ellis; C R Parikh; J K Inrig; M Kanbay; M Kambay; U D Patel
Journal:  Am J Transplant       Date:  2008-11       Impact factor: 8.086

8.  Chronic kidney disease in long-term survivors of myeloablative allogeneic haematopoietic cell transplantation: prevalence and risk factors.

Authors:  Minoru Ando; Kazuteru Ohashi; Hideki Akiyama; Hisashi Sakamaki; Taku Morito; Ken Tsuchiya; Kosaku Nitta
Journal:  Nephrol Dial Transplant       Date:  2009-09-17       Impact factor: 5.992

9.  Long-term renal function after allogenic haematopoietic stem cell transplantation in adult patients: a single-centre study.

Authors:  Maxime Touzot; Caroline Elie; Jill van Massenhove; Natacha Maillard; Agnès Buzyn; Fadi Fakhouri
Journal:  Nephrol Dial Transplant       Date:  2009-10-13       Impact factor: 5.992

10.  Prospective evaluation of acute and chronic renal function in children following matched related donor hematopoietic stem cell transplantation.

Authors:  Talia Ileri; Mehmet Ertem; Zeynep Birsin Ozcakar; Elif Unal Ince; Zeynep Biyikli; Zumrut Uysal; Mesiha Ekim; Fatos Yalcinkaya
Journal:  Pediatr Transplant       Date:  2009-04-06
View more
  7 in total

1.  Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab.

Authors:  Sonata Jodele; Christopher E Dandoy; Adam Lane; Benjamin L Laskin; Ashley Teusink-Cross; Kasiani C Myers; Gregory Wallace; Adam Nelson; Jack Bleesing; Ranjit S Chima; Russel Hirsch; Thomas D Ryan; Stefanie Benoit; Kana Mizuno; Mikako Warren; Stella M Davies
Journal:  Blood       Date:  2020-03-26       Impact factor: 22.113

2.  Treatment with Foscarnet after Allogeneic Hematopoietic Cell Transplant (Allo-HCT) Is Associated with Long-Term Loss of Renal Function.

Authors:  Gena G Foster; Michael J Grant; Samantha M Thomas; Blake Cameron; Doug Raiff; Kelly Corbet; Gavin Loitsch; Christopher Ferreri; Mitchell Horwitz
Journal:  Biol Blood Marrow Transplant       Date:  2020-05-23       Impact factor: 5.742

Review 3.  Acute Kidney Injury and CKD Associated with Hematopoietic Stem Cell Transplantation.

Authors:  Amanda DeMauro Renaghan; Edgar A Jaimes; Jolanta Malyszko; Mark A Perazella; Ben Sprangers; Mitchell Howard Rosner
Journal:  Clin J Am Soc Nephrol       Date:  2019-12-13       Impact factor: 8.237

4.  Late Kidney Morbidity and Mortality in Hematopoietic Cell Transplant Survivors.

Authors:  Natalie L Wu; Sangeeta Hingorani; Kara L Cushing-Haugen; Stephanie J Lee; Eric J Chow
Journal:  Transplant Cell Ther       Date:  2021-02-17

5.  Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation.

Authors:  Nosha Farhadfar; Ajoy Dias; Tao Wang; Caitrin Fretham; Saurabh Chhabra; Hemant S Murthy; Larisa Broglie; Anita D'Souza; Shahinaz M Gadalla; Robert Peter Gale; Shahrukh Hashmi; A Samer Al-Homsi; Gerhard C Hildebrandt; Peiman Hematti; David Rizzieri; Lynette Chee; Hillard M Lazarus; Christopher Bredeson; Edgar A Jaimes; Amer Beitinjaneh; Asad Bashey; Tim Prestidge; Maxwell M Krem; David I Marks; Stefanie Benoit; Jean A Yared; Taiga Nishihori; Richard F Olsson; Cesar O Freytes; Edward Stadtmauer; Bipin N Savani; Mohamed L Sorror; Siddhartha Ganguly; John R Wingard; Marcelo Pasquini
Journal:  Transplant Cell Ther       Date:  2021-02-26

6.  Early bilirubinemia after allogeneic stem cell transplantation-an endothelial complication.

Authors:  Hao Dai; Olaf Penack; Aleksandar Radujkovic; David Schult; Joshua Majer-Lauterbach; Igor Wolfgang Blau; Lars Bullinger; Sihe Jiang; Carsten Müller-Tidow; Peter Dreger; Thomas Luft
Journal:  Bone Marrow Transplant       Date:  2021-01-30       Impact factor: 5.483

7.  Chronic kidney disease, survival and graft-versus-host-disease-free/relapse-free survival in recipients of allogeneic hematopoietic stem cell transplant.

Authors:  Karyne Pelletier; Gabrielle Côté; Kayla Madsen; Shiyi Chen; S Joseph Kim; Christopher T Chan; Jonas Mattsson; Ivan Pasic; Abhijat Kitchlu
Journal:  Clin Kidney J       Date:  2022-04-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.